ENCell News and Resources

ENCell Co., Ltd., a South Korean biotech specialising in biopharmaceutical contract development and manufacturing (CDMO) and novel drug development, has signed a memorandum of understanding (MOU) with Cell Resources Corporation (CRC). The agreement aims to support ENCell’s expansion into the cell and gene therapy

ENCell has secured an 802 million won ($550,000) contract to provide contract development and manufacturing (CDMO) services for CELLeBRAIN, a Korean biotech developing gene-modified stem cell therapies for neurological diseases. The agreement, which runs until December 2025, tasks ENCell with producing CELLeBRAIN’s